- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03335332
High Intensity Exercise for Increasing Fitness in Patients With Hypertrophic Cardiomyopathy
Efficacy of High Intensity Exercise (HIE) for Increasing Cardiorespiratory Fitness in Patients With Hypertrophic Cardiomyopathy (HCM)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Regular exercise reduces the risk of all-cause and cardiovascular mortality in the general population. Specifically, higher cardiorespiratory fitness is associated with a 10 - 20 % reduction in mortality risk for every 1 MET (metabolic equivalent tasks) improvement in fitness. A high degree of fitness is also protective against the development of heart failure and exercise training has become the standard of care for most patients with cardiovascular disease to improve functional capacity, and reduce morbidity and mortality. However, hypertrophic cardiomyopathy, the most common inherited cardiovascular disease, may be an exception. For more than 30 years, hypertrophic cardiomyopathy (HCM) has been identified as the most common cause of death in young athletes, and patients with HCM are excluded from participation in competitive sports. The fear of provocation of sudden cardiac death has often been extended to non-competitive athletic activities in such patients, though there is a distinct lack of evidence about the safety of exercise in this population. A recent multicenter clinical trial provided evidence that moderate intensity exercise (MIE) may be safe in this population, though the increase in fitness with this training paradigm was modest. Alternatively, an extensive series of reviews published over the last five years advocate for high intensity interval training (HIIT) as an efficacious stimulus for increasing cardiorespiratory fitness in clinical adult populations, including those with heart failure. While a pilot investigation and preliminary findings suggest that moderate to vigorous intensity exercise may be safe and efficacious in patients with HCM, and even protective in animal models, there is no Level A or B evidence comparing the efficacy or safety of MIE and high intensity exercise (HIE) training in this patient population to guide exercise prescription. Therefore, the primary purpose of this exercise trial is to compare the efficacy and safety of supervised MIE and HIE training in adults with HCM. Specific aims and hypotheses of the project are as follows:
Aim 1: Compare the efficacy of a high intensity and moderate intensity exercise intervention to improve cardiorespiratory fitness and functional diastolic reserve in patients with HCM.
- Primary hypothesis: HIE will result in greater increases in maximal oxygen uptake (V̇O2max) than MIE in patients with HCM.
- Secondary hypothesis: HIE will improve stroke volume reserve to a greater degree than MIE in patients with HCM.
Aim 2: To evaluate the safety of HIE training in patients with HCM.
- Hypothesis: Regular exercise training of a high or moderate intensity will be safe (no serious adverse events) in this patient population. Specifically, it is hypothesised that HIE will not increase arrhythmia burden in patients with HCM.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75231
- The Institute for Exercise and Environmental Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients aged 18 - 80 years old
- Diagnosed HCM defined by the presence of unexplained left-ventricular hypertrophy with end-diastolic wall thickness ≥ 15 mm on 2D echocardiography or wall thickness between 13 and 15 mm along with at least one other piece of evidence of hypertrophic cardiomyopathy, such as systolic anterior motion of the mitral valve leaflets, family history of hypertrophic cardiomyopathy, or positive genetic test result.
Exclusion Criteria:
- A history of exercise-induced syncope or arrhythmias (ventricular tachycardia; sustained or non-sustained)
- Left ventricular outflow obstruction (≥ 50 mm Hg at rest)
- Less than 3 months post septal reduction therapy (surgery or catheter based intervention)
- Pregnancy
- Worsening clinical status or advanced heart failure (New York Heart Association class IV symptoms)
- A hypotensive responsive to exercise (an increase in exercise systolic BP throughout the exercise test of < 20mmHg compared with resting values, or an initial increase in systolic BP > 20mmHg with a subsequent fall by peak exercise of > 20mmHg, or a continuous decrease in systolic BP throughout the test of > 20mmHg, compared with baseline BP)
- Left ventricular systolic dysfunction (left ventricular ejection fraction < 55 % by echocardiography)
- Coronary artery disease as evidenced by prior myocardial infarction or angina
- Cerebrovascular disease as evidenced by prior transient ischemic attack or stroke
- A chronic orthopaedic injury which limits the ability to exercise
- Subjects unable to speak English will not be recruited because of the complex experimental studies and the need for precise communication between the volunteers and the research staff to ensure safety.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: High intensity exercise
A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles.
Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes).
Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded.
The first few exercise training sessions will supervised at our hospital based fitness centre until the subject is confident to complete the training independently.
All HIIT sessions will be supervised over the intervention.
|
The exercise groups will receive identical exercise prescription for the first two months of the intervention, after which the HIE group will incorporate HIIT in their exercise regimen.
The reason for this approach is to include a period of general conditioning and progressively increase intensity prior to submitting volunteers to HIE.
This approach considers participant safety as arrhythmias may be uncovered during the first two months of MIE training.
It will also improve participant compliance by increasing exercise self-efficacy and confidence prior to commencing HIIT.
|
|
Active Comparator: Moderate intensity exercise
|
A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles.
Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes).
Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded.
The first few exercise training sessions in both exercise groups (MIE and HIE) will supervised at our hospital based fitness centre until the subject is confident to complete the training independently.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiorespiratory fitness
Time Frame: Five months
|
Change in maximal oxygen uptake (V̇O2max)
|
Five months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional diastolic reserve
Time Frame: Five months
|
Change in stroke volume reserve
|
Five months
|
|
Safety - Number of adverse events
Time Frame: Ten months
|
Adverse events during the study will be recorded
|
Ten months
|
|
Safety - Number of arrhythmic events
Time Frame: Ten months
|
Number of arrhythmic events will be assessed by an implantable loop recorder
|
Ten months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU 072017-048
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertrophic Cardiomyopathy
-
Xiang WeiActive, not recruitingTransapical Beating-Heart Septal Myectomy for Symptomatic Nonobstructive Hypertrophic CardiomyopathyNonobstructive Hypertrophic CardiomyopathyChina
-
Bristol-Myers SquibbCompletedHypertrophic Cardiomyopathy | Non-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyDenmark, United States, Belgium, Czechia, France, Germany, Israel, Netherlands, Poland, Portugal, Spain, United Kingdom, Italy
-
French Cardiology SocietyCompleted1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy | 2- Obstructive Hypertrophic Cardiomyopathy | 3- Non Obstructive Hypertrophic CardiomyopathyFrance
-
Montreal Heart InstituteCanadian Institutes of Health Research (CIHR)Enrolling by invitationCardiomyopathies | Hypertrophic Cardiomyopathy | Hypertrophic Obstructive Cardiomyopathy | Familial Hypertrophic CardiomyopathyCanada
-
Lexicon PharmaceuticalsRecruitingNon-obstructive Hypertrophic Cardiomyopathy | Obstructive Cardiomyopathy, HypertrophicUnited States, United Kingdom, Argentina, Serbia, Belgium, Georgia, Israel, Brazil, Croatia, France, Germany, Hungary, Poland, Portugal, Romania, Bulgaria, Italy, Sweden, Czechia
-
University of Sao PauloCompletedNon-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyBrazil
-
Tampere UniversityUniversity of Bologna; University College Dublin; University of Oxford; Rennes... and other collaboratorsActive, not recruitingHCM - Hypertrophic CardiomyopathyFinland
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingHypertrophic Cardiomyopathy (HCM)China
-
SuZhou Sinus Medical Technologies Co.,LtdRecruitingHypertrophic Cardiomyopathy, ObstructiveChina
-
BayerActive, not recruitingObstructive Hypertrophic CardiomyopathyJapan
Clinical Trials on High intensity exercise
-
Robert Ross, PhDRecruiting
-
Laboratoire des Adaptations Métaboliques à l'Exercice...CREPS Auvergne Rhône-Alpes / VichyCompletedOverweight | PostmenopausalFrance
-
Georgia State UniversityEmory UniversityWithdrawn
-
University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI)WithdrawnMyocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Coronary Disease
-
National Institute of Neurological Disorders and...TerminatedTraumatic Brain InjuryUnited States
-
Cardiff Metropolitan UniversityCardiff UniversityCompletedPolycystic Ovary Syndrome | Exercise | Cerebrovascular CirculationUnited Kingdom
-
University of MiamiCompletedSedentary LifestyleUnited States
-
Universidade Federal do CearaCompletedDiabetes MellitusBrazil
-
University of ValenciaNot yet recruiting
-
USDA Beltsville Human Nutrition Research CenterUnited States Army Research Institute of Environmental MedicineCompletedHealthy VolunteersUnited States